Loading...

You're on the old version of Simply Wall St. We will no longer be supporting this site, so we recommend you switch to our brand new platform.

Icure Pharm

KOSDAQ:A175250
Snowflake Description

Imperfect balance sheet and overvalued.

The Snowflake is generated from 30 checks in 5 different areas, read more below.
A175250
KOSDAQ
₩150B
Market Cap
  1. Home
  2. KR
  3. Household
Company description

Icure Pharm. Inc., a biopharmaceutical company, researches, develops, and sells pharmaceutical and cosmetic products. The last earnings update was 28 days ago. More info.


Add to Portfolio Compare Print
  • Icure Pharm has significant price volatility in the past 3 months.
A175250 Share Price and Events
7 Day Returns
20%
KOSDAQ:A175250
12.5%
KR Personal Products
6.7%
KR Market
1 Year Returns
-45.6%
KOSDAQ:A175250
-20.8%
KR Personal Products
-18.5%
KR Market
A175250 Shareholder Return
  7 Day 30 Day 90 Day 1 Year 3 Year 5 Year
Icure Pharm (A175250) 20% -8.7% -33.1% -45.6% - -
KR Personal Products 12.5% -0.8% -14.9% -20.8% -18.8% -35.4%
KR Market 6.7% -6.7% -16% -18.5% -14.8% -19.6%
1 Year Return vs Industry and Market
  • A175250 underperformed the Personal Products industry which returned -20.8% over the past year.
  • A175250 underperformed the Market in Korea (Republic of) which returned -18.5% over the past year.
Price Volatility
Industry
5yr Volatility vs Market

Value

 Is Icure Pharm undervalued based on future cash flows and its price relative to the stock market?

Value is all about what a company is worth versus what price it is available for. If you went into a grocery store and all the bananas were on sale at half price, they could be considered undervalued.
INTRINSIC VALUE BASED ON FUTURE CASH FLOWS
  • It is not possible to calculate the future cash flow value for Icure Pharm. This is due to cash flow or dividend data being unavailable. The share price is ₩23700.
PRICE RELATIVE TO MARKET
We can also value a company based on what the stock market is willing to pay for it. This is similar to the price of fruit (e.g. Mangoes or Avocados) increasing when they are out of season, or how much your home is worth.

The amount the stock market is willing to pay for Icure Pharm's earnings, growth and assets is considered below, and whether this is a fair price.
Price based on past earnings
Are Icure Pharm's earnings available for a low price, and how does this compare to other companies in the same industry?
Raw Data
KOSDAQ:A175250 PE (Price to Earnings) Ratio Data Sources
Data Point Source Value
Earnings Per Share * Company Filings (2019-12-31) in KRW ₩-1,387.79
KOSDAQ:A175250 Share Price ** KOSDAQ (2020-04-09) in KRW ₩23700
Korea (Republic of) Personal Products Industry PE Ratio Median Figure of 24 Publicly-Listed Personal Products Companies 24.7x
Korea (Republic of) Market PE Ratio Median Figure of 1,320 Publicly-Listed Companies 13.09x

* Trailing twelve months (TTM) annual GAAP earnings per share excluding extraordinary items.

** Primary Listing of Icure Pharm.

KOSDAQ:A175250 PE (Price to Earnings) Ratio Calculation
Calculation Outcome
PE Ratio

= KOSDAQ:A175250 Share Price ÷ EPS (both in KRW)

= 23700 ÷ -1,387.79

-17.08x

Learn more about our ratios and growth rates in Simply Wall St’s analysis model >

  • Icure Pharm is loss making, we can't compare its value to the KR Personal Products industry average.
  • Icure Pharm is loss making, we can't compare the value of its earnings to the Korea (Republic of) market.
Price based on expected Growth
Does Icure Pharm's expected growth come at a high price?
Raw Data
KOSDAQ:A175250 PEG (Price to Earnings to Growth) Ratio Data Sources
Data Point Source Value
PE Ratio See PE Ratio Section -17.08x
Net Income Annual Growth Rate See Future Growth Section.
Line of Best Fit* through Consensus Estimate Earnings of 0 Analysts
Not available
Korea (Republic of) Personal Products Industry PEG Ratio Median Figure of 12 Publicly-Listed Personal Products Companies 1.24x
Korea (Republic of) Market PEG Ratio Median Figure of 353 Publicly-Listed Companies 0.8x

*Line of best fit is calculated by linear regression .

Learn more about our ratios and growth rates in Simply Wall St’s analysis model >

  • Unable to calculate PEG ratio for Icure Pharm, we can't assess if its growth is good value.
Price based on value of assets
What value do investors place on Icure Pharm's assets?
Raw Data
KOSDAQ:A175250 PB (Price to Book) Ratio Data Sources
Data Point Source Value
Book Value per Share Company Filings (2019-12-31) in KRW ₩15,445.12
KOSDAQ:A175250 Share Price * KOSDAQ (2020-04-09) in KRW ₩23700
Korea (Republic of) Personal Products Industry PB Ratio Median Figure of 41 Publicly-Listed Personal Products Companies 1.75x
Korea (Republic of) Market PB Ratio Median Figure of 1,980 Publicly-Listed Companies 0.92x
KOSDAQ:A175250 PB (Price to Book) Ratio Calculation
Calculation Outcome
PB Ratio

= KOSDAQ:A175250 Share Price ÷ Book Value per Share (both in KRW)

= 23700 ÷ 15,445.12

1.53x

* Primary Listing of Icure Pharm.

Learn more about our ratios and growth rates in Simply Wall St’s analysis model >

  • Icure Pharm is good value based on assets compared to the KR Personal Products industry average.
X
Value checks
We assess Icure Pharm's value by looking at:
  1. Is the discounted cash flow value less than 20%, or 40% of the share price? (2 checks) ( Click here or on bar chart for details of DCF calculation. )
  2. Is the PE ratio less than the market average, and/ or less than the Personal Products industry average (and greater than 0)? (2 checks)
  3. Is the PEG ratio within a reasonable range (0 to 1)? (1 check)
  4. Is the PB ratio less than the Personal Products industry average (and greater than 0)? (1 check)
  5. Icure Pharm has a total score of 1/6, see the detailed checks below.

    Note: We use GAAP Earnings per Share in all our calculations including PE and PEG Ratio.

    Full details on the Value part of the Simply Wall St company analysis model.

Future Performance

 How is Icure Pharm expected to perform in the next 1 to 3 years based on estimates from 0 analysts?

In this section we usually present revenue and earnings growth projections based on the consensus estimates of professional analysts to help investors understand the company’s ability to generate profit. But as Icure Pharm has not provided enough past data and has no analyst forecast, its future earnings cannot be reliably calculated by extrapolating past data or using analyst predictions.

This is quite a rare situation as 97% of companies covered by Simply Wall St do have past financial data. You can see them here.

Show me the analysis anyway

The future performance of a company is measured in the same way as past performance, by looking at estimated growth and how much profit it is expected to make.

Future estimates come from professional analysts. Just like forecasting the weather, they don’t always get it right!
Annual Growth Rate
18.7%
Expected Personal Products industry annual growth in earnings.
Earnings growth vs Low Risk Savings
Is Icure Pharm expected to grow at an attractive rate?
  • Unable to compare Icure Pharm's earnings growth to the low risk savings rate as no estimate data is available.
Growth vs Market Checks
  • Unable to compare Icure Pharm's earnings growth to the Korea (Republic of) market average as no estimate data is available.
  • Unable to compare Icure Pharm's revenue growth to the Korea (Republic of) market average as no estimate data is available.
Annual Growth Rates Comparison
Raw Data
KOSDAQ:A175250 Future Growth Rates Data Sources
Data Point Source Value (per year)
Korea (Republic of) Personal Products Industry Earnings Growth Rate Market Cap Weighted Average 18.7%
Korea (Republic of) Personal Products Industry Revenue Growth Rate Market Cap Weighted Average 7.4%
Korea (Republic of) Market Earnings Growth Rate Market Cap Weighted Average 27.5%
Korea (Republic of) Market Revenue Growth Rate Market Cap Weighted Average 6.7%

*Line of best fit is calculated by linear regression .

Industry and Market average data is calculated daily.

Learn more about our growth rate calculations in Simply Wall St’s analysis model.

Analysts growth expectations
Raw Data
KOSDAQ:A175250 Analysts Growth Expectations Data Sources
Data Point Source Value
Past Financials Company Filings (3 months ago) See Below
Future Estimates Average of up to 0 Analyst Estimates (S&P Global) See Below
All numbers in KRW Millions and using Trailing twelve months (TTM) annual period rather than quarterly.
KOSDAQ:A175250 Future Estimates Data
Date (Data in KRW Millions) Revenue Cash Flow Net Income * Avg. No. Analysts
KOSDAQ:A175250 Past Financials Data
Date (Data in KRW Millions) Revenue Cash Flow Net Income *
2019-12-31 60,922 -5,943 -8,751
2019-09-30 49,822 -6,898 4,978
2019-06-30 37,867 -9,900 -1,848
2019-03-31 31,479 -8,321 -11,411
2018-12-31 33,320 -7,304 -7,885
2018-09-30 36,227 -5,321 -6,647
2018-06-30 40,747 -658 -3,916
2018-03-31 40,230 2,094 2,704
2017-12-31 39,796 1,119 538
2017-09-30 37,952 500 -813
2017-06-30 32,964 -2,880 -1,231
2017-03-31 30,189 -4,390 -2,889

*GAAP earnings excluding extraordinary items.

Super high growth metrics
High Growth Checks
  • Unable to determine if Icure Pharm is high growth as no earnings estimate data is available.
  • Unable to determine if Icure Pharm is high growth as no revenue estimate data is available.
Past and Future Earnings per Share
The accuracy of the analysts who estimate the future performance data can be gauged below. We look back 3 years and see if they were any good at predicting what actually occurred. We also show the highest and lowest estimates looking forward to see if there is a wide range.
Raw Data
KOSDAQ:A175250 Past and Future Earnings per Share
Data Point Source Value
Past Financials Company Filings (3 months ago) See Below
Future Estimates Average of up to 0 Analyst Estimates (S&P Global) See Below

All data from Icure Pharm Company Filings, last reported 3 months ago, and in Trailing twelve months (TTM) annual period rather than quarterly.

KOSDAQ:A175250 Future Estimates Data
Date (Data in KRW Millions) EPS * EPS High Estimate EPS Low Estimate Avg. No. Analysts
KOSDAQ:A175250 Past Financials Data
Date (Data in KRW Millions) EPS *
2019-12-31 -1,387.79
2019-09-30 794.56
2019-06-30 -307.65
2019-03-31 -1,955.47
2018-12-31 -1,436.04
2018-09-30 -1,285.61
2018-06-30 -735.04
2018-03-31 551.25
2017-12-31 110.00
2017-09-30 -165.97
2017-06-30 -266.47
2017-03-31 -596.48

*GAAP earnings excluding extraordinary items.

Performance in 3 years
In the same way as past performance we look at the future estimated return (profit) compared to the available funds. We do this looking forward 3 years.
  • Unable to establish if Icure Pharm will efficiently use shareholders’ funds in the future without estimates of Return on Equity.

Next steps:

  1. Icure Pharm's future outlook can be gauged by looking at industry trends and market size, and determining how well-positioned the company is compared to its competitors. Take a look at other high-growth Household companies here
  2. Use fundamentals to screen for another stock to analyse from our database of over 75,000 companies worldwide
X
Future performance checks
We assess Icure Pharm's future performance by looking at:
  1. Is the annual earnings growth rate expected to beat the low risk savings rate, plus a premium to keep pace with inflation?
  2. Is the annual earnings growth rate expected to beat the average growth rate in earnings of the Korea (Republic of) market? (1 check)
  3. Is the annual revenue growth rate expected to beat the average growth rate in revenue of the Korea (Republic of) market? (1 check)
  4. Is the annual earnings growth rate expected to be above 20%? (1 check)
  5. Is the annual revenue growth rate expected to be above 20%? (1 check)
  6. Is the Return on Equity in 3 years expected to be over 20%? (1 check)
Some of the above checks will fail if the company is expected to be loss making in the relevant year.
Icure Pharm has a total score of 0/6, see the detailed checks below.

Note 1: We use GAAP Net Income Excluding Exceptional Items for our Earnings in all our calculations.

Full details on the Future part of the Simply Wall St company analysis model.

Past Performance

  How has Icure Pharm performed over the past 5 years?

The past performance of a company can be measured by how much growth it has experienced and how much profit it makes relative to the funds and assets it has available.
Past earnings growth
Below we compare Icure Pharm's growth in the last year to its industry (Personal Products).
Past Earnings growth analysis
We also check if the company has grown in the past 5 years, and whether it has maintained that growth in the year.
  • Icure Pharm does not make a profit and their year on year earnings growth rate was negative over the past 5 years.
  • Unable to compare Icure Pharm's 1-year earnings growth to the 5-year average as it is not currently profitable.
  • Unable to compare Icure Pharm's 1-year growth to the KR Personal Products industry average as it is not currently profitable.
Earnings and Revenue History
Icure Pharm's revenue and profit over the past 5 years is shown below, any years where they have experienced a loss will show up in red.
Raw Data

All data from Icure Pharm Company Filings, last reported 3 months ago, and in Trailing twelve months (TTM) annual period rather than quarterly.

KOSDAQ:A175250 Past Revenue, Cash Flow and Net Income Data
Date (Data in KRW Millions) Revenue Net Income * G+A Expenses R&D Expenses
2019-12-31 60,922.49 -8,750.78 21,156.04 1,685.42
2019-09-30 49,821.68 4,977.71 18,270.38 2,888.68
2019-06-30 37,866.69 -1,848.00 17,313.23 2,792.89
2019-03-31 31,479.44 -11,410.53 17,252.79 2,118.79
2018-12-31 33,320.49 -7,885.10 17,539.41 2,090.10
2018-09-30 36,226.94 -6,646.98 16,463.63 1,156.17
2018-06-30 40,746.55 -3,915.97 16,155.54 859.34
2018-03-31 40,230.34 2,704.33 13,378.23 639.55
2017-12-31 39,796.33 537.95 12,262.65 599.03
2017-09-30 37,951.71 -813.00 11,416.63 620.17
2017-06-30 32,963.82 -1,231.22 7,999.57 691.23
2017-03-31 30,189.08 -2,889.20 7,544.46 878.52
2016-12-31 27,278.89 -3,242.89 6,932.44 871.41
2016-09-30 23,914.15 -3,366.93 5,894.95 898.31
2016-06-30 19,516.74 -3,811.28 5,240.72 849.47
2016-03-31 17,966.60 -3,301.00 4,614.30 806.99
2015-12-31 18,673.48 -2,877.56 3,875.17 669.98
2014-12-31 14,930.23 957.75 1,008.91 217.93

*GAAP earnings excluding extraordinary items.

Performance last year
We want to ensure a company is making the most of what it has available. This is done by comparing the return (profit) to a company's available funds, assets and capital.
  • It is difficult to establish if Icure Pharm has efficiently used shareholders’ funds last year (Return on Equity greater than 20%) as it is loss-making.
  • It is difficult to establish if Icure Pharm has efficiently used its assets last year compared to the KR Personal Products industry average (Return on Assets) as it is loss-making.
  • It is difficult to establish if Icure Pharm improved its use of capital last year versus 3 years ago (Return on Capital Employed) as it is currently loss-making.
X
Past performance checks
We assess Icure Pharm's performance over the past 5 years by checking for:
  1. Has earnings increased in past 5 years? (1 check)
  2. Has the earnings growth in the last year exceeded that of the Personal Products industry? (1 check)
  3. Is the recent earnings growth over the last year higher than the average annual growth over the past 5 years? (1 check)
  4. Is the Return on Equity (ROE) higher than 20%? (1 check)
  5. Is the Return on Assets (ROA) above industry average? (1 check)
  6. Has the Return on Capital Employed (ROCE) increased from 3 years ago? (1 check)
The above checks will fail if the company has reported a loss in the most recent earnings report. Some checks require at least 3 or 5 years worth of data.
Icure Pharm has a total score of 0/6, see the detailed checks below.

Note: We use GAAP Net Income excluding extraordinary items in all our calculations.

Full details on the Past part of the Simply Wall St company analysis model.

Health

 How is Icure Pharm's financial health and their level of debt?

A company's financial position is much like your own financial position, it includes everything you own (assets) and owe (liabilities).

The boxes below represent the relative size of what makes up Icure Pharm's finances.

The net worth of a company is the difference between its assets and liabilities.
Net Worth
  • Icure Pharm is able to meet its short term (1 year) commitments with its holdings of cash and other short term assets.
  • Icure Pharm's long term commitments exceed its cash and other short term assets.
Balance sheet
This treemap shows a more detailed breakdown of Icure Pharm's finances. If any of them are yellow this indicates they may be out of proportion and red means they relate to one of the checks below.
Assets
Liabilities and shares
The 'shares' portion represents any funds contributed by the owners (shareholders) and any profits.
  • High level of physical assets or inventory.
  • Debt is not covered by short term assets, assets are 0.8x debt.
Historical Debt
Nearly all companies have debt. Debt in itself isn’t bad, however if the debt is too high, or the company can’t afford to pay the interest on its debts this may have impacts in the future.

The graphic below shows equity (available funds) and debt, we ideally want to see the red area (debt) decreasing.

If there is any debt we look at the companies capability to repay it, and whether the level has increased over the past 5 years.
Raw Data

All data from Icure Pharm Company Filings, last reported 3 months ago.

KOSDAQ:A175250 Past Debt and Equity Data
Date (Data in KRW Millions) Total Equity Total Debt Cash & Short Term Investments
2019-12-31 100,077.07 82,838.40 36,174.69
2019-09-30 98,035.01 67,969.39 40,949.33
2019-06-30 97,017.62 62,767.76 49,078.77
2019-03-31 92,744.63 33,243.88 35,114.15
2018-12-31 84,692.72 20,989.71 53,443.14
2018-09-30 86,136.85 20,987.97 58,878.19
2018-06-30 13,112.07 23,158.12 1,826.45
2018-03-31 19,287.81 22,882.04 4,731.61
2017-12-31 17,276.50 21,844.74 9,549.76
2017-09-30 17,751.81 11,092.66 1,123.66
2017-06-30 17,087.85 11,544.82 2,392.69
2017-03-31 16,806.79 10,700.63 4,585.36
2016-12-31 16,945.20 5,800.66 1,611.13
2016-09-30 18,103.06 4,942.52 11,179.40
2016-06-30 13,627.66 9,318.72 13,850.79
2016-03-31 5,276.81 13,576.28 10,428.46
2015-12-31 5,962.70 13,405.25 14,087.06
2014-12-31 400.96 7,681.42 132.57
  • Icure Pharm's level of debt (82.8%) compared to net worth is high (greater than 40%).
  • The level of debt compared to net worth has been reduced over the past 5 years (1849.4% vs 82.8% today).
CASH RUNWAY ANALYSIS

For companies that have on average been loss making in the past we assess whether they have at least 1 year of cash runway.

  • Icure Pharm has less than a year of cash runway based on current free cash flow.
  • Icure Pharm has less than a year of cash runway if free cash flow continues to grow at historical rates of 59.2% each year.
X
Financial health checks
We assess Icure Pharm's financial health by checking for:
  1. Are short term assets greater than short term liabilities? (1 check)
  2. Are short term assets greater than long term liabilities? (1 check)
  3. Has the debt to equity ratio increased in the past 5 years? (1 check)
  4. Is the debt to equity ratio over 40%? (1 check)
  5. Is the debt covered by operating cash flow? (1 check)
  6. Are earnings greater than 5x the interest on debt (if company pays interest at all)? (1 check)
  7. Icure Pharm has a total score of 2/6, see the detailed checks below.
For companies that are loss making and have been so on average in the past we replace the last 2 checks with:
  1. Does cash and short term investments cover stable operating expenses (recurring G&A and R&D) for more than 3 years? (1 check)
  2. Does cash and short term investments cover growing operating expenses (recurring G&A and R&D) for more than 3 years? (1 check)


Full details on the Health part of the Simply Wall St company analysis model.

Dividends

 What is Icure Pharm's current dividend yield, its reliability and sustainability?

Dividends are regular cash payments to you from the company, similar to a bank paying you interest on a savings account.
Annual Dividend Income
Dividend payments
0%
Current annual income from Icure Pharm dividends.
If you bought ₩2,000 of Icure Pharm shares you are expected to receive ₩0 in your first year as a dividend.
Dividend Amount
Here we look how much dividend is being paid, if any. Is it above what you can get in a savings account? It is up there with the best dividend paying companies?
  • Unable to evaluate Icure Pharm's dividend yield against the bottom 25% of dividend payers as the company has not reported any payouts.
  • Unable to evaluate Icure Pharm's dividend against the top 25% market benchmark as the company has not reported any payouts.
Annualized Historical and Future Dividends
It is important to see if the dividend for a company is stable, and not wildly increasing/decreasing each year. This graph shows you the historical rate to count toward your assessment of the stock.

We also check to see if the dividend has increased in the past 10 years.
Raw Data
KOSDAQ:A175250 Annualized Past and Future Dividends
Data Point Source Value
Past Annualized Dividend Yield S&P Global Market Data See Below
Past Dividends per Share Company Filings/ Annualized Dividend Payments See Below
Future Dividends per Share Estimates Average of up to 0 Analyst Estimates (S&P Global) See Below
Korea (Republic of) Personal Products Industry Average Dividend Yield Market Cap Weighted Average of 18 Stocks 0.8%
Korea (Republic of) Market Average Dividend Yield Market Cap Weighted Average of 913 Stocks 2.8%
Korea (Republic of) Minimum Threshold Dividend Yield 10th Percentile 0.6%
Korea (Republic of) Bottom 25% Dividend Yield 25th Percentile 1.2%
Korea (Republic of) Top 25% Dividend Yield 75th Percentile 3.7%

Industry and Market average data is calculated daily.

Note all dividend per share amounts are annualized and not quarterly or other period.

KOSDAQ:A175250 Future Dividends Estimate Data
Date (Data in ₩) Dividend per Share (annual) Avg. No. Analysts

Learn more about our ratios and growth rates in Simply Wall St’s analysis model >

  • Unable to perform a dividend volatility check as Icure Pharm has not reported any payouts.
  • Unable to verify if Icure Pharm's dividend has been increasing as the company has not reported any payouts.
Current Payout to shareholders
What portion of Icure Pharm's earnings are paid to the shareholders as a dividend.
  • Unable to calculate sustainability of dividends as Icure Pharm has not reported any payouts.
Future Payout to shareholders
  • Insufficient estimate data to determine if a dividend will be paid in 3 years and that it will be sustainable.
X
Income/ dividend checks
We assess Icure Pharm's dividend by checking for:
  1. Firstly is the company paying a notable dividend (greater than 0.6%) - if not then the rest of the checks are ignored.
  2. Is current dividend yield above the bottom 25% of dividend payers? (1 check)
  3. Is current dividend yield above the top 25% of dividend payers? (1 check)
  4. Have they paid a dividend for 10 years, and during this period has the dividend been volatile (drop of more than 25%)? (1 check)
  5. If they have paid a dividend for 10 years has it increased in this time? (1 check)
  6. How sustainable is the dividend, can Icure Pharm afford to pay it from its earnings today and in 3 years (Payout ratio less than 90%)? (2 checks)
  7. Icure Pharm has a total score of 0/6, see the detailed checks below.


Full details on the Dividends part of the Simply Wall St company analysis model.

Management

 What is the CEO of Icure Pharm's salary, the management and board of directors tenure and is there insider trading?

Management is one of the most important areas of a company. We look at unreasonable CEO compensation, how long the team and board of directors have been around for and insider trading.
  • Icure Pharm has no CEO, or we have no data on them.
Management Team
Board of Directors
Who owns this company?
Recent Insider Trading
  • No 3 month open market individual insider trading information.
Recent Insider Transactions
Announced Type Name Entity Role Start End Shares Max Price (₩) Value (₩)
X
Management checks
We assess Icure Pharm's management by checking for:
  1. Is the CEO's compensation unreasonable compared to market cap? (1 check)
  2. Has the CEO's compensation increased more than 20% whilst the EPS is down more then 20%? (1 check)
  3. Is the average tenure of the management team less than 2 years? (1 check)
  4. Is the average tenure of the board of directors team less than 3 years? (1 check)
  5. Icure Pharm has a total score of 0/6, this is not included on the snowflake, see the detailed checks below.


Note: We use the top 6 management executives and board members in our calculations.

Note 2: Insider trading include any internal stakeholders and these transactions .

Full details on the Management part of the Simply Wall St company analysis model.

News

Simply Wall St News

Company Info

Description

Icure Pharm. Inc., a biopharmaceutical company, researches, develops, and sells pharmaceutical and cosmetic products. The company offers OTC products, including NSAIDs, sprint cool and smoking cessation products, eye lotions, vitamins, and myalgia products; ETC products, such as Rivastigmine and Tulobuterol patches, and Lidogesic and oral products; and quasi drugs comprising concentrated gargles, as well as teeth whitening strips, gels, and devices. It also provides gel masks and skin care products. The company was founded in 2000 and is based in Seoul, South Korea.

Details
Name: Icure Pharm. Inc.
A175250
Exchange: KOSDAQ
Founded: 2000
₩149,657,773,800
6,314,674
Website: http://www.icure.co.kr
Address: Icure Pharm. Inc.
10, Bongeunsa-ro 104-gil,
Gangnam-gu,
Seoul,
06170,
South Korea
Listings
Exchange Symbol Ticker Symbol Security Exchange Country Currency Listed on
KOSDAQ A175250 Common Stock KOSDAQ KR KRW 12. Jul 2018
Number of employees
Current staff
Staff numbers
0
Icure Pharm employees.
Industry
Personal Products
Household
Company Analysis and Financial Data Status
Area Date (UTC time)
Company Analysis updated: 2020/04/09 19:56
End of day share price update: 2020/04/09 00:00
Last estimates confirmation: 2020/02/06
Last earnings filing: 2020/03/12
Last earnings reported: 2019/12/31
Last annual earnings reported: 2019/12/31


All dates and times in UTC. All financial data provided by Standard & Poor’s Capital IQ.

Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.